{
  "source": "PA-Notification-Tabrecta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1321-5\nProgram Prior Authorization/Notification\nMedication Tabrecta® (capmatinib)\nP&T Approval Date 7/2020, 7/2021, 7/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nTabrecta (capmatinib) is a kinase inhibitor indicated for the treatment of adult patients with\nmetastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to\nmesenchymal-epithelial transition (MET) exon 14 skipping.\nThe National Cancer Comprehensive Network (NCCN) guideline also recommends use of\nTabrecta as single-agent therapy for NSCLC with high-level MET amplification.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Tabrecta will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Tabrecta will be approved based on all of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(b) One of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\ni. Presence of mesenchymal-epithelial transition (MET) exon 14 skipping\npositive tumors\nii. High level MET amplification in lung cancer\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tabrecta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tabrecta\ntherapy\nAuthorization will ",
    "for 12 months.\n2. Reauthorization\na. Tabrecta will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Tabrecta\ntherapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tabrecta [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation,\nMarch 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed June 4, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Notification – Tabrecta® (capmatinib)\nChange Control\n7/2020 New program.\n7/2021 Updated coverage criteria for NSCLC according to NCCN guidelines.\n7/2022 Annual review. Added state mandate with no other changes to criteria.\nUpdated references.\n7/2023 Annual review. Updated background with FDA regular approval.\nUpdated references.\n7/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}